according to the OSHA Hazard Communication Standard



Mirtazapine Disintegrating Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 09/30/2023
9.0	04/06/2024	50205-00023	Date of first issue: 01/23/2015

SECTION 1. IDENTIFICATION

Product name	:	Mirtazapine Disintegrating Formulation			
Manufacturer or supplier's details					
Company name of supplier	:	Organon & Co.			
Address	:	30 Hudson Street, 33nd floor			
		Jersey City, New Jersey, U.S.A 07302			
Telephone	:	1-551-430-6000			
Emergency telephone	:	1-215-631-6999			
E-mail address	:	EHSSTEWARD@organon.com			
Recommended use of the c	hen	nical and restrictions on use			
Recommended use	:	Pharmaceutical			
Restrictions on use	:	Not applicable			

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR	
1910.1200)	
Combustible dust	

Acute toxicity (Oral)	:	Category 4
Reproductive toxicity	:	Category 2
Specific target organ toxicity - repeated exposure (Oral)	:	Category 2 (Nervous system)
GHS label elements Hazard pictograms	:	
Signal Word	:	Warning
Hazard Statements	:	If small particles are generated during further processing, han- dling or by other means, may form combustible dust concentra- tions in air. H302 Harmful if swallowed. H361fd Suspected of damaging fertility. Suspected of damaging the unborn child. H373 May cause damage to organs (Nervous system) through prolonged or repeated exposure if swallowed.
Precautionary Statements	:	Prevention: P201 Obtain special instructions before use. P202 Do not handle until all safety precautions have been read and understood.

according to the OSHA Hazard Communication Standard



Mirtazapine Disintegrating Formulation

Version 9.0	Revision Date: 04/06/2024	SDS Number: 50205-00023	Date of last issue: 09/30/2023 Date of first issue: 01/23/2015
		P270 Do not e	in thoroughly after handling. at, drink or smoke when using this product. otective gloves, protective clothing, eye protection
		unwell. Rinse r	- P330 IF SWALLOWED: Call a doctor if you feel mouth. F exposed or concerned: Get medical attention.
		Storage: P405 Store loc	
		Disposal: P501 Dispose disposal plant.	of contents and container to an approved waste

Other hazards

Dust contact with the eyes can lead to mechanical irritation. Contact with dust can cause mechanical irritation or drying of the skin.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
(+/-)-1,2,3,4,10,14b-Hexahydro-2- methylpyrazino[2,1-a]pyrido[2,3- c][2]benzazepine	85650-52-8	>= 20 - < 30
Citric acid	77-92-9	>= 1 - < 5
Cellulose	9004-34-6	>= 1 - < 5
Aspartame	22839-47-0	>= 1 - < 5
Magnesium stearate	557-04-0	>= 1 - < 5
Actual concentration is withheld as a	a trade secret	•

Actual concentration is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

General advice	advice immedia	accident or if you feel unwell, seek medical ately. Is persist or in all cases of doubt seek medical
If inhaled	: If inhaled, remo	
	Get medical at	ention.
In case of skin contact	: In case of cont of water.	act, immediately flush skin with soap and plenty
	Remove contai	ninated clothing and shoes.
	Get medical at	•
	Wash clothing	before reuse.
		an shoes before reuse.
In case of eye contact	: If in eyes, rinse	
in case of cye contact	-	
	Get medical at	ention if irritation develops and persists.

according to the OSHA Hazard Communication Standard



Mirtazapine Disintegrating Formulation

Version 9.0	Revision Date: 04/06/2024	SDS Number: 50205-00023	Date of last issue: 09/30/2023 Date of first issue: 01/23/2015
Mos	rallowed t important symptoms effects, both acute and yed	Get medical a Rinse mouth t Never give an : Harmful if swa Suspected of unborn child. May cause da exposure if swa	horoughly with water. ything by mouth to an unconscious person. allowed. damaging fertility. Suspected of damaging the mage to organs through prolonged or repeated
	ection of first-aiders es to physician	: First Aid respondent First Aid respondent Aid respondent First Aid First Aid F	with the eyes can lead to mechanical irritation. onders should pay attention to self-protection, ecommended personal protective equipment ential for exposure exists (see section 8). natically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO2) Dry chemical
Unsuitable extinguishing media	:	None known.
Specific hazards during fire fighting	:	Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
Hazardous combustion prod- ucts	:	Carbon oxides Nitrogen oxides (NOx) Metal oxides
Specific extinguishing meth- ods	:	Use extinguishing measures that are appropriate to local cir- cumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for fire-fighters	:	In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protec- tive equipment and emer- gency procedures	:	Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

according to the OSHA Hazard Communication Standard



Mirtazapine Disintegrating Formulation

Version 9.0	Revision Date: 04/06/2024	-	9S Number: 205-00023	Date of last issue: 09/30/2023 Date of first issue: 01/23/2015
Methods and materials for : containment and cleaning up		:	container for disp Avoid dispersal of with compressed Dust deposits sho surfaces, as these released into the Local or national disposal of this m employed in the c determine which r Sections 13 and 1	dust in the air (i.e., clearing dust surfaces
SECTIO	N 7. HANDLING AND ST	OR	AGE	
Tec	hnical measures	:	causing an explos	precautions, such as electrical grounding

	and bollang, of more autoophoroo.
ation	Use only with adequate ventilation.

		and borraing, or more almoophoreer
Local/Total ventilation	:	Use only with adequate ventilation.
Advice on safe handling	:	Do not breathe dust.
		Do not swallow.
		Avoid contact with eyes.
		Avoid prolonged or repeated contact with skin.
		Wash skin thoroughly after handling.
		Handle in accordance with good industrial hygiene and safety
		practice, based on the results of the workplace exposure
		assessment
		Minimize dust generation and accumulation.
		Keep container closed when not in use.
		Keep away from heat and sources of ignition.
		Take precautionary measures against static discharges.
		Do not eat, drink or smoke when using this product.
		Take care to prevent spills, waste and minimize release to the
		environment.
Conditions for safe storage	•	Keep in properly labeled containers.
	•	Store locked up.
		Store in accordance with the particular national regulations.
Materials to avoid		Do not store with the following product types:
	•	Strong oxidizing agents

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

	inert or nuisance dust	50 Million particles per cubic foot Value type (Form of exposure): TWA (total dust) Basis: OSHA Z-3
--	------------------------	---

according to the OSHA Hazard Communication Standard



Mirtazapine Disintegrating Formulation

ersion .0	Revision Date: 04/06/2024	SDS Number: 50205-00023		t issue: 09/30/2023 t issue: 01/23/2015			
		15 mg/m³ Value type (Fe Basis: OSHA		: TWA (total dust)			
		5 mg/m³ Value type (Fo Basis: OSHA		: TWA (respirable fra	action)		
				oot): TWA (respirable fra	action)		
Dust, ticula	nuisance dust and par- tes		10 mg/m³ Value type (Form of exposure): PEL (Total dust) Basis: CAL PEL				
			5 mg/m³ Value type (Form of exposure): PEL (respirable dust fraction) Basis: CAL PEL				
Com	ponents	CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis		
Hexa meth	1,2,3,4,10,14b- hydro-2- ylpyrazino[2,1- ido[2,3-c][2]benzazepine	85650-52-8	TŴA	25 µg/m³	Internal		
			Wipe limit	250 µg/100 cm ²	Internal		
Cellu	lose	9004-34-6	TWA	10 mg/m ³	ACGIH		
			TWA (Res- pirable)	5 mg/m³	NIOSH REL		
			TWA (total)	10 mg/m ³	NIOSH REL		
			TWA (total dust)	15 mg/m ³	OSHA Z-1		
			TWÁ (respir- able fraction)	5 mg/m ³	OSHA Z-1		
Magr	nesium stearate	557-04-0	TWA (Inhal- able particu- late matter)	10 mg/m ³	ACGIH		
			TWA (Res- pirable par- ticulate mat- ter)	3 mg/m³	ACGIH		

Engineering measures

Ensure adequate ventilation, especially in confined areas. Minimize workplace exposure concentrations. Apply measures to prevent dust explosions. Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).

Personal protective equipment

:

according to the OSHA Hazard Communication Standard



Mirtazapine Disintegrating Formulation

Version 9.0	Revision Date: 04/06/2024	SDS Number 50205-00023			
Respiratory protection		maintain concentra unknown Follow O use NIOS by air pur hazardou supplied release, e circumsta	General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.		
Hand	protection				
Material		: Chemical	-resistant gloves		
Re	emarks	on the co time is no For speci resistanc gloves wi	loves to protect hands against chemicals depending ncentration specific to place of work. Breakthrough t determined for the product. Change gloves often! al applications, we recommend clarifying the to chemicals of the aforementioned protective th the glove manufacturer. Wash hands before and at the end of workday.		
Eye p	protection		following personal protective equipment:		
Skin	and body protection	: Select ap resistanc potential. Skin cont	propriate protective clothing based on chemical e data and an assessment of the local exposure act must be avoided by using impervious protective gloves, aprons, boots, etc).		
Hygie	ene measures	: If exposu eye flush working p When us	re to chemical is likely during typical use, provide ng systems and safety showers close to the		

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	powder
Color	:	No data available
Odor	:	No data available
Odor Threshold	:	No data available
рН	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available

according to the OSHA Hazard Communication Standard



Mirtazapine Disintegrating Formulation

Versior 9.0	n	Revision Date: 04/06/2024		S Number: 205-00023	Date of last issue: 09/30/2023 Date of first issue: 01/23/2015
E١	vapora	ation rate	:	No data available	9
Fl	Flammability (solid, gas)		:	May form explosi handling or other	ive dust-air mixture during processing, means.
Fla	amma	ability (liquids)	:	No data available	9
		explosion limit / Upper bility limit	:	No data available	9
		explosion limit / Lower bility limit	:	No data available	9
Va	apor p	pressure	:	No data available	9
Re	elative	e vapor density	:	No data available	9
De	ensity		:	No data available	9
So		ty(ies) er solubility	:	No data available	9
		n coefficient: n- /water	:	No data available	9
		ition temperature	:	No data available	9
De	ecomp	position temperature	:	No data available	9
Vi	iscosit Visc	y osity, dynamic	:	No data available	
	Visc	osity, kinematic	:	No data available	9
E>	xplosiv	ve properties	:	Not explosive	
O	xidizin	ng properties	:	The substance o	r mixture is not classified as oxidizing.
M	olecul	ar weight	:	No data available	9
	article article	characteristics size	:	No data available	9

SECTION 10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reac-	:	May form explosive dust-air mixture during processing,
tions		handling or other means.
		Can react with strong oxidizing agents.

according to the OSHA Hazard Communication Standard



Version 9.0	Revision Date: 04/06/2024	SDS Number: 50205-00023	Date of last issue: 09/30/2023 Date of first issue: 01/23/2015				
Conditions to avoid Incompatible materials Hazardous decomposition products		Avoid dust f : Oxidizing ag	 Heat, flames and sparks. Avoid dust formation. Oxidizing agents No hazardous decomposition products are known. 				
SECTION	ECTION 11. TOXICOLOGICAL INFORMATION						
Inhala Skin o Ingest	contact	es of exposure					
	e toxicity ful if swallowed.						
<u>Produ</u> Acute	<u>uct:</u> oral toxicity		y estimate: 1,588 mg/kg culation method				
Comr	oonents:						
		vdro_2_mothylpyra	zino[2,1-a]pyrido[2,3-c][2]benzazepine:				
	oral toxicity		320 - 490 mg/kg				
Citric	acid:						
Acute	oral toxicity	: LD50 (Mous	e): 5,400 mg/kg				
	dermal toxicity		> 2,000 mg/kg CD Test Guideline 402 : The substance or mixture has no acute dermal				
II Cellul	050.						
	oral toxicity	: LD50 (Rat):	> 5,000 mg/kg				
Acute	inhalation toxicity	: LC50 (Rat): Exposure tin Test atmosp					
Acute	dermal toxicity	: LD50 (Rabb	it): > 2,000 mg/kg				
II Asnai	rtame:						
	oral toxicity	: LD50 (Rat):	> 5,000 mg/kg				
Magn	esium stearate:						
	oral toxicity		> 2,000 mg/kg CD Test Guideline 423 : The substance or mixture has no acute oral tox-				

Method Result

according to the OSHA Hazard Communication Standard



Mirtazapine Disintegrating Formulation

ersion .0	Revision Date: 04/06/2024	SDS Number: 50205-00023	Date of last issue: 09/30/2023 Date of first issue: 01/23/2015
П		icity	
		Remarks: I	Based on data from similar materials
Acute	e dermal toxicity		bit): > 2,000 mg/kg Based on data from similar materials
Skin	corrosion/irritation		
	lassified based on av	ailable information.	
	ponents:		
	c acid:		
Spec		: Rabbit	
Meth Resu		: OECD Tes : No skin irri	t Guideline 404
Resu	in and the second se	. INO SKIIT ITT	lation
Magr	nesium stearate:		
Spec	ies	: Rabbit	
Resu		: No skin irri	
Rema	arks	: Based on o	data from similar materials
Citric Spec	: acid: ies	: Rabbit	
Resu		: Irritation to	eyes, reversing within 21 days
Meth	od	: OECD Tes	t Guideline 405
Magr	nesium stearate:		
Spec		: Rabbit	
Resu		: No eye irrit	ation
Rema	arks		data from similar materials
Resp	piratory or skin sens	itization	
-	sensitization		
	lassified based on av	ailable information.	
Resn	biratory sensitization		
-	lassified based on av		
<u>Com</u>	ponents:		
Magr	nesium stearate:		
Test	Туре	: Maximizati	on Test
Route	es of exposure	: Skin conta	
Spec		: Guinea pig	
Meth Resu		: OECD Tes	t Guideline 406
RASII			

: negative

according to the OSHA Hazard Communication Standard



ersion 0	Revision Date: 04/06/2024	SDS Number:Date of last issue: 09/30/202350205-00023Date of first issue: 01/23/2015
Rema	ırks	: Based on data from similar materials
Not cl	cell mutagenicity assified based on av conents:	ailable information.
		ydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:
	toxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative
		Test Type: In vitro mammalian cell gene mutation test Test system: Chinese hamster lung cells Result: negative
		Test Type: unscheduled DNA synthesis assay Test system: mammalian cells Result: negative
		Test Type: sister chromatid exchange assay Test system: mammalian cells Result: negative
Geno	toxicity in vivo	: Test Type: Micronucleus test Species: Rat Cell type: Bone marrow Application Route: Oral Result: negative
Citric	aaid	
	toxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative
		Test Type: in vitro micronucleus test Result: positive
		Test Type: Bacterial reverse mutation assay (AMES) Result: negative
Geno	toxicity in vivo	: Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis) Species: Rat Application Route: Ingestion Result: negative
Cellu	lose:	
	toxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative
		Test Type: In vitro mammalian cell gene mutation test Result: negative

according to the OSHA Hazard Communication Standard



Mirtazapine Disintegrating Formulation

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Ingestion Aspartame: Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES) Result: negative Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro) Result: negative Genotoxicity in vivo Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis) Species: Rat Application Route: Ingestion Application Route: Ingestion Result: negative Magnesium stearate: : Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test Result: negative Remarks: Based on data from similar materials Test Type: Chromosome aberration test in vitro Method: OECD Test Guideline 473 Result: negative Remarks: Based on data from similar materials Test Type: Bacterial reverse mutation assay (AMES) Result: negative Remarks: Based on data from similar materials Test Type: Bacterial reverse mutation assay (AMES) Result: negative Remarks: Based on data from similar materials Test Type: Bacterial reverse mutation assay (AMES) Result: negative Remarks: Based on data from simi	/ersion).0	Revision Date: 04/06/2024		st issue: 09/30/2023 st issue: 01/23/2015
Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES) Result: negativeGenotoxicity in vivo: Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro) Result: negativeGenotoxicity in vivo: Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis) Species: Rat Application Route: Ingestion Result: negativeMagnesium stearate:Image: Test Type: In vitro mammalian cell gene mutation test Result: negative Remarks: Based on data from similar materials Test Type: Chromosome aberration test in vitro 	Geno	toxicity in vivo	cytogenetic assay) Species: Mouse Application Route: Ingestion	rocyte micronucleus test (in vivo
Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES) Result: negativeGenotoxicity in vivo: Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro) Result: negativeGenotoxicity in vivo: Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis) Species: Rat Application Route: Ingestion Result: negativeMagnesium stearate:Image: Test Type: In vitro mammalian cell gene mutation test 	Aspa	rtame:		
Genotoxicity in vivo : Test Type: Mutagenicity (in vitro) Result: negative Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis) Species: Rat Application Route: Ingestion Result: negative Magnesium stearate: : Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test Result: negative Remarks: Based on data from similar materials Test Type: Chromosome aberration test in vitro Method: OECD Test Guideline 473 Result: negative Remarks: Based on data from similar materials Test Type: Bacterial reverse mutation assay (AMES) Result: negative Remarks: Based on data from similar materials Test Type: Bacterial reverse mutation assay (AMES) Result: negative Remarks: Based on data from similar materials Test Type: Bacterial reverse mutation assay (AMES) Result: negative Remarks: Based on data from similar materials Carcinogenicity Not classified based on available information.	-			mutation assay (AMES)
cytogenetic test, chromosomal analysis) Species: Rat Application Route: Ingestion Result: negative Magnesium stearate: Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test Result: negative Remarks: Based on data from similar materials Test Type: Chromosome aberration test in vitro Method: OECD Test Guideline 473 Result: negative Remarks: Based on data from similar materials Test Type: Bacterial reverse mutation assay (AMES) Result: negative Remarks: Based on data from similar materials Test Type: Bacterial reverse mutation assay (AMES) Result: negative Remarks: Based on data from similar materials Test Type: Bacterial reverse mutation assay (AMES) Result: negative Remarks: Based on data from similar materials Test Type: Bacterial reverse mutation assay (AMES) Result: negative Remarks: Based on data from similar materials Descriptive Remarks: Based on data from similar materials			thesis in mammalian cells (in	
Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test Result: negative Remarks: Based on data from similar materials Test Type: Chromosome aberration test in vitro Method: OECD Test Guideline 473 Result: negative Remarks: Based on data from similar materials Test Type: Bacterial reverse mutation assay (AMES) Result: negative Remarks: Based on data from similar materials Test Type: Bacterial reverse mutation assay (AMES) Result: negative Remarks: Based on data from similar materials Test Type: Bacterial reverse mutation assay (AMES) Result: negative Remarks: Based on data from similar materials Carcinogenicity Not classified based on available information.	Geno	toxicity in vivo	cytogenetic test, chromosoma Species: Rat Application Route: Ingestion	
Result: negative Remarks: Based on data from similar materials Test Type: Chromosome aberration test in vitro Method: OECD Test Guideline 473 Result: negative Remarks: Based on data from similar materials Test Type: Bacterial reverse mutation assay (AMES) Result: negative Remarks: Based on data from similar materials Carcinogenicity Not classified based on available information.	Magr	nesium stearate:		
Method: OECD Test Guideline 473 Result: negative Remarks: Based on data from similar materials Test Type: Bacterial reverse mutation assay (AMES) Result: negative Remarks: Based on data from similar materials Carcinogenicity Not classified based on available information.	Geno	toxicity in vitro	Result: negative	-
Result: negative Remarks: Based on data from similar materials Carcinogenicity Not classified based on available information.			Method: OECD Test Guidelin Result: negative	e 473
Not classified based on available information.			Result: negative	
	Carci	nogenicity		
Components:	Not c	lassified based on av	ilable information.	
	<u>Com</u>	ponents:		

(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:

Species	: Mouse
Application Route	: Oral
Exposure time	: 18 month(s)
LOAEL	: 200 mg/kg body weight
Result	: equivocal
Target Organs	: Liver
Species	: Rat
Application Route	: Oral
Exposure time	: 2 Years
LOAEL	: 20 mg/kg body weight
Result	: equivocal

according to the OSHA Hazard Communication Standard



Version 9.0	Revision Date: 04/06/2024	SDS Number: 50205-00023	Date of last issue: 09/30/2023 Date of first issue: 01/23/2015
Target	Organs	: Liver, Thyroid	
		: Rat : Ingestion : 72 weeks : negative	
	s ition Route ire time Group 2B: F	: Rat : Ingestion : 104 weeks : negative Possibly carcinogenic	
	Aspartame		22839-47-0
OSHA		ent of this product pre list of regulated carcir	sent at levels greater than or equal to 0.1% is nogens.
NTP			ent at levels greater than or equal to 0.1% is ed carcinogen by NTP.
Suspec <u>Compo</u> (+/-)-1, Effects	onents:	 rdro-2-methylpyrazin Test Type: Fer Species: Rat Application Ro Fertility: LOAE Symptoms: Eff tions. Result: Animal Embryotoxic ef detected. t Test Type: Dev Species: Rat Application Ro Developmenta Result: Embryo offspring were Test Type: Dev Species: Rabb Application Ro Developmenta 	L: 15 mg/kg body weight ect on estrous cycle, Increase of early resorp- testing did not show any effects on fertility., fects and adverse effects on the offspring were velopment ute: Oral I Toxicity: LOAEL: 100 mg/kg body weight btoxic effects and adverse effects on the detected., No teratogenic effects. velopment it

according to the OSHA Hazard Communication Standard



Mirtazapine Disintegrating Formulation

Version 9.0	Revision Date: 04/06/2024		9S Number: 205-00023	Date of last issue: 09/30/2023 Date of first issue: 01/23/2015
Reproo sessm	ductive toxicity - As- ent	:	fertility, based on	f adverse effects on sexual function and animal experiments., Some evidence of n development, based on animal
Citric	acid:			
Effects	on fetal development	:	Test Type: One-g Species: Rat Application Route Result: negative	eneration reproduction toxicity study : Ingestion
Cellul	200			
	on fertility	:	Test Type: One-g Species: Rat Application Route Result: negative	eneration reproduction toxicity study
Effects	on fetal development	:	Test Type: Fertilit Species: Rat Application Route Result: negative	y/early embryonic development : Ingestion
II Acnor	tomo			
Aspar Effects	s on fertility	:	Test Type: Two-g Species: Rat Application Route Result: negative	eneration reproduction toxicity study : Ingestion
Effects	on fetal development	:	Test Type: Embry Species: Rat Application Route Result: negative	ro-fetal development : Ingestion
	· · · · · · · · · · · · · · · · · · ·			
	esium stearate:	:	reproduction/deve Species: Rat Application Route Method: OECD To Result: negative	
Effects	on fetal development	:	Species: Rat Application Route Result: negative	ro-fetal development : Ingestion on data from similar materials

STOT-single exposure

Not classified based on available information.

Revision Date:

04/06/2024

Version

9.0

according to the OSHA Hazard Communication Standard



Date of last issue: 09/30/2023

Date of first issue: 01/23/2015

Mirtazapine Disintegrating Formulation

SDS Number:

50205-00023

Citric acid:	
Assessment	: May cause respiratory irritation.
STOT-repeated exposur	e
May cause damage to org	gans (Nervous system) through prolonged or repeated exposure if
Components:	
	hydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:
Routes of exposure	: Ingestion
Target Organs	: Nervous system
Assessment	: May cause damage to organs through prolonged or repe exposure.
Repeated dose toxicity	
Components:	
(+/-)-1,2,3,4,10,14b-Hexa	hydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:
Species	: Rat
LOAEL	: 120 mg/kg
Application Route	: Oral
Exposure time	: 13 Weeks
Target Organs	: Nervous system
Species	: Dog
LOAEL	: 15 mg/kg
Application Route	: Oral
Exposure time	: 52 Weeks
Target Organs Symptoms	: Nervous system : Tremors
Cymptollia	. Hemory
Species	: Dog
LOAEL	: 20 mg/kg
Application Route	: Oral
Exposure time	: 13 Weeks
Target Organs Symptoms	: Nervous system, Testis : Tremors
Oymptoms	. Henors
Citric acid:	
Species	: Rat
NOAEL	: 4,000 mg/kg
LOAEL	: 8,000 mg/kg
Application Route	: Ingestion
Exposure time	: 10 Days
Cellulose:	
Species	: Rat
NOAEL	: >= 9,000 mg/kg

according to the OSHA Hazard Communication Standard



Mirtazapine Disintegrating Formulation

Version 9.0	Revision Date: 04/06/2024	SDS Number: 50205-00023	Date of last issue: 09/30/2023 Date of first issue: 01/23/2015
Applica Expos	ation Route ure time	: Ingestion : 90 Days	
Aspar	tame:		
		: Rat : >= 4,000 mg/kg : Ingestion : 104 Weeks	
Magne	esium stearate:		
Specie NOAE Applica	es L ation Route ure time	: Rat : > 100 mg/kg : Ingestion : 90 Days : Based on data fro	m similar materials

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:

	•	
Ingestion	:	Symptoms: Drowsiness, constipation, dry mouth, asthenia, Dizziness, Disorientation
		Dizziness, Disorientation

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:

Toxicity to fish	:	LC50 (Pimephales promelas (fathead minnow)): 6.92 mg/l Exposure time: 96 h Method: FDA 4.11
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): 19.5 mg/l Exposure time: 48 h
Toxicity to algae/aquatic plants	:	EC50 (Pseudokirchneriella subcapitata (green algae)): 5.7 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
		NOEC (Pseudokirchneriella subcapitata (green algae)): 3.2 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
Toxicity to fish (Chronic tox-	:	NOEC (Pimephales promelas (fathead minnow)): 3.6 mg/l

according to the OSHA Hazard Communication Standard



Version 9.0	Revision Date: 04/06/2024	-	9S Number: 205-00023	Date of last issue: 09/30/2023 Date of first issue: 01/23/2015
icity)			Exposure time: 31 Method: OECD Te	
	y to daphnia and other c invertebrates (Chron- city)	:	NOEC (Daphnia r Exposure time: 21 Method: OECD Te	
Toxicit	y to microorganisms	:	EC50 (Natural mid Exposure time: 3 Test Type: Respir Method: OECD Te	ation inhibition
			NOEC (Natural m Exposure time: 3 Test Type: Respir Method: OECD Te	ation inhibition
Citric	acid:			
	y to fish	:	LC50 (Pimephales Exposure time: 96	s promelas (fathead minnow)): > 100 mg/l S h
	y to daphnia and other c invertebrates	:	EC50 (Daphnia m Exposure time: 24	agna (Water flea)): 1,535 mg/l ł h
Cellul	ose:			
Toxicit	y to fish	:	Exposure time: 48	ipes (Japanese medaka)): > 100 mg/l 3 h on data from similar materials
Aspar	tame:			
	y to fish	:	LC50 (Danio rerio Exposure time: 96	(zebra fish)): > 20 g/l S h
	y to daphnia and other c invertebrates	:	EC50 (Daphnia m Exposure time: 48 Method: OECD Te	
Toxicit plants	y to algae/aquatic	:	ErC50 (Desmodes Exposure time: 72 Method: OECD Te	smus subspicatus (green algae)): > 100 mg/l 2 h est Guideline 201
II Magny	esium stearate:			
	y to fish	:	Exposure time: 48 Method: DIN 3841	
	y to daphnia and other c invertebrates	:	Exposure time: 47 Test substance: V	agna (Water flea)): > 1 mg/l 7 h Vater Accommodated Fraction 67/548/EEC, Annex V, C.2.

according to the OSHA Hazard Communication Standard



Version 9.0	Revision Date: 04/06/2024	-	S Number: 05-00023	Date of last issue: 09/30/2023 Date of first issue: 01/23/2015
			Remarks: Based No toxicity at the	on data from similar materials limit of solubility.
Toxic plants	ity to algae/aquatic S		mg/l Exposure time: 72 Test substance: \ Method: OECD T	Vater Accommodated Fraction est Guideline 201 on data from similar materials
			mg/l Exposure time: 72 Test substance: \ Method: OECD T	Vater Accommodated Fraction
Toxic	ity to microorganisms		Exposure time: 10 Test substance: V	onas putida): > 100 mg/l 5 h Vater Accommodated Fraction on data from similar materials
II Persi	stence and degradabi	lity		
Com	ponents:			
	acid:			
Biode	egradability		Result: Readily bi Biodegradation: Exposure time: 28 Method: OECD T	97 %
Cellu	lose:			
Biode	egradability	:	Result: Readily b	odegradable.
Aspa	rtame:			
Biode	egradability		Result: Readily b Method: OECD T	odegradable. est Guideline 301F
Magn	nesium stearate:			
Biode	egradability	:	Result: Not biode Remarks: Based	gradable on data from similar materials
Bioad	ccumulative potential			
Com	ponents:			
		dro-2-	methylpyrazinol	2,1-a]pyrido[2,3-c][2]benzazepine:
	cumulation	:	Species: Oncorhy	rnchus mykiss (rainbow trout) factor (BCF): 334

according to the OSHA Hazard Communication Standard



Mirtazapine Disintegrating Formulation

Version 9.0	Revision Date: 04/06/2024		DS Number: 0205-00023	Date of last issue: 09/30/2023 Date of first issue: 01/23/2015
I			Method: OECD T	est Guideline 305
	ition coefficient: n- nol/water	:	log Pow: 2.78	
Citr	ic acid:			
	ition coefficient: n- nol/water	:	log Pow: -1.72	
Asp	artame:			
	ition coefficient: n- nol/water	:	log Pow: 0.07 Remarks: Calcula	ation
Mag	nesium stearate:			
	ition coefficient: n- nol/water	:	log Pow: > 4	
Mot	oility in soil			
<u>Con</u>	nponents:			
(+/-)	-1,2,3,4,10,14b-Hexahyd	dro-	2-methylpyrazino	[2,1-a]pyrido[2,3-c][2]benzazepine:
	ribution among environ- tal compartments	:	log Koc: 4.48	
Oth	er adverse effects			
No d	data available			
SECTIO	N 13. DISPOSAL CONSI	DEF	RATIONS	
Disp	oosal methods			
-	te from residues	:		ordance with local regulations. f waste into sewer.
Con	taminated packaging	:		should be taken to an approved waste

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

handling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

according to the OSHA Hazard Communication Standard



Mirtazapine Disintegrating Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 09/30/2023
9.0	04/06/2024	50205-00023	Date of first issue: 01/23/2015

Not regulated as a dangerous good

Special precautions for user

Not applicable

49 CFR

SECTION 15. REGULATORY INFORMATION

CERCLA Reportable Quantity

This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards	:	Combustible dust Acute toxicity (any route of exposure) Reproductive toxicity Specific target organ toxicity (single or repeated exposure)
SARA 313	:	This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis)

reporting levels established by SARA Title III, Section 313.

US State Regulations

IECSC

Pennsylvania Right To Know					
	D-mannitol	69-65-8			
	(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1- a]pyrido[2,3-c][2]benzazepine	85650-52-8			
	Polyvinyl pyrrolidone	9003-39-8			
	Cellulose	9004-34-6			
Californi	ia List of Hazardous Substances				
	Polyvinyl pyrrolidone	9003-39-8			
Californi	a Permissible Exposure Limits for Chemical Contaminants				
	Cellulose	9004-34-6			
	Magnesium stearate	557-04-0			
The ingr	edients of this product are reported in the following invento	ries:			
AICS	: not determined				
DSL	: not determined				

: not determined

according to the OSHA Hazard Communication Standard



Mirtazapine Disintegrating Formulation


Version	Revision Date:	SDS Number:	Date of last issue: 09/30/2023
9.0	04/06/2024	50205-00023	Date of first issue: 01/23/2015

SECTION 16. OTHER INFORMATION

Further information



HMIS® IV:



Full text of other abbreviations

ACGIH CAL PEL		USA. ACGIH Threshold Limit Values (TLV) California permissible exposure limits for chemical contami- nants (Title 8, Article 107)
NIOSH REL	:	USA. NIOSH Recommended Exposure Limits
OSHA Z-1	:	USA. Occupational Exposure Limits (OSHA) - Table Z-1 Limits for Air Contaminants
OSHA Z-3	:	USA. Occupational Exposure Limits (OSHA) - Table Z-3 Mineral Dusts
ACGIH / TWA	:	8-hour, time-weighted average
CAL PEL / PEL	:	Permissible exposure limit
NIOSH REL / TWA	:	Time-weighted average concentration for up to a 10-hour workday during a 40-hour workweek
OSHA Z-1 / TWA	:	8-hour time weighted average
OSHA Z-3 / TWA	:	8-hour time weighted average

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime

according to the OSHA Hazard Communication Standard



Mirtazapine Disintegrating Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 09/30/2023
9.0	04/06/2024	50205-00023	Date of first issue: 01/23/2015

Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Revision Date : 04/06/2024

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8